IV Ketamine vs Spravato: A Provider’s Guide to Both Treatment Paths
Providers across the country face a familiar scene in 2026. A patient with treatment resistant depression sits across the desk and asks one direct question: “Should I do IV ketamine or Spravato?” The answer depends on clinical goals, insurance coverage, practice infrastructure, and regulatory tolerance. This guide breaks down both treatment paths so providers can make confident recommendations and build sustainable programs around one or both options.
Key Takeaways
| Key Takeaway | What It Means |
|---|---|
| IV ketamine uses racemic ketamine off label | Providers have full dosing flexibility but no FDA approval for depression |
| Spravato (esketamine) holds FDA approval for treatment resistant depression | Insurance coverage is available but REMS certification adds administrative overhead |
| IV ketamine costs $400 to $800 per session out of pocket | Patients without insurance coverage for Spravato often prefer IV for faster access |
| Both pathways require in office monitoring | Clinics need dedicated observation space, trained staff, and safety protocols regardless of route |
| Offering both treatments strengthens a practice | Dual programs capture insured and cash pay patients, maximizing revenue and access |
| Response rates are comparable between both treatments | Clinical decisions should focus on patient factors, not blanket superiority claims |
What Is IV Ketamine Therapy?
IV ketamine therapy delivers racemic ketamine directly into the bloodstream through an intravenous infusion. Racemic ketamine contains both the S enantiomer and R enantiomer in equal parts. The FDA approved ketamine as an anesthetic in 1970, but providers prescribe it off label for treatment resistant depression, anxiety, PTSD, and chronic pain. No FDA approval exists for these psychiatric indications.
A typical IV ketamine session lasts 40 to 60 minutes. Providers administer doses between 0.5 mg/kg and 1.0 mg/kg, adjusting based on patient response and tolerance. Most protocols call for six infusions over two to three weeks during the induction phase. Maintenance infusions follow every three to six weeks depending on symptom recurrence. Use the HealingMaps clinic directory to find providers offering IV ketamine in your area.
The off label status gives providers significant clinical freedom. Dosing, frequency, and adjunctive therapies like ketamine assisted psychotherapy all fall within the provider’s clinical judgment. This flexibility attracts practitioners who want to personalize treatment plans without rigid protocol constraints.
What Is Spravato (Esketamine)?
Spravato is the brand name for esketamine nasal spray, manufactured by Janssen Pharmaceuticals. The FDA approved Spravato in March 2019 for treatment resistant depression in adults. A second indication followed in August 2020 for major depressive disorder with acute suicidal ideation or behavior. These approvals make Spravato the only FDA approved ketamine derivative for psychiatric use.
Esketamine is the isolated S enantiomer of ketamine. It binds to the NMDA receptor with roughly four times the affinity of the R enantiomer. Patients self administer the nasal spray under direct supervision in a certified healthcare setting. Each session takes about two hours, including a mandatory post dose monitoring period. Standard dosing starts at 56 mg and increases to 84 mg based on tolerability.
The FDA approval carries weight in clinical conversations. Patients and referring physicians often view Spravato as the “legitimate” option because of its regulatory status. Insurance companies are more likely to cover an FDA approved treatment, which lowers the financial barrier for many patients.
Mechanism of Action: Racemic vs S Enantiomer
Both IV ketamine and Spravato target the NMDA receptor, but their pharmacological profiles differ. Racemic ketamine delivers two distinct molecules that interact with multiple receptor systems. The S enantiomer provides strong NMDA antagonism. The R enantiomer contributes additional activity at opioid receptors, sigma receptors, and other targets that researchers believe support antidepressant and anti anxiety effects.
Spravato delivers only the S enantiomer. This focused mechanism produces potent NMDA blockade but lacks the broader receptor activity of the full racemic mixture. Some clinicians argue that the R enantiomer’s contribution to mood regulation and dissociative experience makes racemic ketamine a more complete therapeutic agent. Published head to head trials remain limited, and the debate continues in clinical circles. A comprehensive review in the American Journal of Psychiatry details the pharmacological distinctions between racemic ketamine and esketamine.
Both treatments trigger a cascade of downstream effects. NMDA receptor blockade increases glutamate release, which activates AMPA receptors and stimulates brain derived neurotrophic factor (BDNF) production. BDNF promotes synaptogenesis, the formation of new neural connections. This process reverses some of the synaptic damage caused by chronic depression.
Administration and Clinical Workflow Differences
IV ketamine requires venous access, infusion pumps, and staff trained in IV administration. A nurse or provider starts the IV line, programs the infusion rate, and monitors the patient throughout the session. Vital signs are tracked at regular intervals. The clinical workflow resembles an outpatient infusion center model.
Spravato simplifies the delivery method. Patients self administer the nasal spray device under observation. No IV access is needed. Staff hand the patient the device, observe administration, and then monitor for two hours. The clinical workflow is lighter on medical equipment but heavier on time per session due to the extended monitoring requirement.
Staffing models differ as well. IV ketamine clinics need nurses or providers comfortable with IV placement and infusion management. Spravato clinics need staff trained in REMS protocols, documentation, and patient observation. Both models require emergency preparedness including blood pressure monitoring equipment, oxygen, and protocols for managing dissociation or cardiovascular changes.
Understanding REMS Requirements for Spravato
The Risk Evaluation and Mitigation Strategy (REMS) program is the single largest operational difference between IV ketamine and Spravato. The FDA mandates REMS certification for every healthcare setting that dispenses Spravato. This program exists because of concerns about sedation, dissociation, and misuse potential.
REMS certification requires the healthcare setting to enroll in the Spravato REMS program, train all dispensing staff, and maintain compliance documentation. Patients must also enroll in the program before receiving their first dose. Each treatment session requires the provider to confirm the patient has not taken other CNS depressants and can arrange transportation home.
The pharmacy distribution model adds another layer. Spravato ships directly to certified treatment centers through specialty pharmacies. Clinics cannot stock Spravato from standard pharmaceutical distributors. Each shipment requires documentation, and clinics must track and report every dose dispensed. Providers who find this administrative load excessive often prefer IV ketamine’s simpler supply chain, where generic ketamine is available through standard compounding or wholesale pharmacy channels.
Cost Comparison: Cash Pay vs Insurance Coverage
Cost remains the deciding factor for many patients. IV ketamine typically runs $400 to $800 per infusion session. A standard six session induction phase costs $2,400 to $4,800 out of pocket. Most commercial insurance plans do not cover IV ketamine for psychiatric indications because it lacks FDA approval for depression. Some practices offer financing plans or package pricing to reduce sticker shock.
Spravato carries a higher list price per session, often exceeding $800 at wholesale. However, commercial insurance and Medicare Part B frequently cover it because of the FDA approval. Janssen also operates a patient savings program that reduces copays for eligible patients. The net out of pocket cost for insured patients often drops to $10 to $50 per session.
For providers, the revenue model differs dramatically. IV ketamine generates strong per session revenue from cash pay patients, but volume depends on the local market’s willingness to pay out of pocket. Spravato brings insurance reimbursement, which attracts a broader patient base but introduces billing complexity, prior authorization delays, and lower per session margins after administrative costs.
Efficacy: What the Clinical Evidence Shows
Spravato earned FDA approval through Phase III clinical trials demonstrating statistically significant improvement in depression scores compared to placebo nasal spray plus oral antidepressant. Response rates in these trials ranged from 50% to 70% for treatment resistant depression. Sustained remission data through long term extension studies showed continued benefit with maintenance dosing.
IV ketamine has a deep evidence base from over two decades of clinical use and research. Hundreds of published studies report response rates of 60% to 75% for treatment resistant depression. Many clinicians observe that IV ketamine produces faster and more robust responses in the first 24 to 48 hours compared to Spravato. The bioavailability of IV delivery approaches 100%, while intranasal absorption sits closer to 48%.
Direct comparison trials between the two remain scarce. The existing evidence does not conclusively prove one treatment is superior. Practice experience suggests IV ketamine excels for rapid stabilization and patients who need precise dose titration. Spravato works well for patients who prefer a less invasive delivery method and have insurance coverage to support ongoing treatment.
Onset Speed and Treatment Timeline
IV ketamine produces noticeable effects within hours of the first infusion. Many patients report significant mood improvement within 24 hours. This rapid onset makes IV ketamine valuable for acute depressive episodes and patients with suicidal ideation who need fast relief. The induction series of six infusions over two to three weeks builds cumulative benefit.
Spravato’s onset is also rapid compared to traditional antidepressants, but clinical response typically emerges over the first two to four weeks of twice weekly treatment. The intranasal route delivers lower peak plasma concentrations than IV infusion, which contributes to the slightly slower onset. After the induction phase, patients transition to weekly and then every other week maintenance sessions.
IV Ketamine vs Spravato: Side by Side Comparison
The chart below summarizes the core clinical, operational, and financial differences between IV ketamine and Spravato. Providers evaluating which treatment to offer or recommend will find this comparison useful for quick reference during clinical and business planning.
Clinic Setup Requirements
An IV ketamine clinic needs a comfortable treatment room with reclining chairs or beds, IV infusion equipment, cardiac monitoring capability, and emergency supplies. Many practices operate in standard medical office suites with minimal build out. A registered nurse or provider must be present during every infusion. Documentation focuses on standard medical records and controlled substance tracking.
A Spravato clinic shares the need for comfortable observation space but adds REMS specific requirements. The clinic must maintain a separate secure storage area for Spravato devices, complete REMS enrollment paperwork for every patient, and file reports with the program. Staff training on REMS procedures takes several hours and requires periodic renewal. The treatment space must allow two hour observation periods with blood pressure monitoring.
Clinics offering both treatments benefit from shared infrastructure. The observation rooms, monitoring equipment, and clinical staff serve both programs. The incremental cost of adding a second treatment pathway is lower than building each program from scratch. Shared overhead improves per treatment margins for both service lines.
Which Patients Are Best for Each Treatment?
IV ketamine is often the stronger choice for patients who need rapid symptom relief, those in acute suicidal crisis, patients with comorbid chronic pain, and individuals who prefer a shorter in office time commitment. Patients who are self pay or have high deductible health plans and want control over their treatment timeline also gravitate toward IV ketamine.
Spravato fits well for patients with commercial insurance or Medicare coverage, those who prefer a non invasive delivery method, and patients whose referring providers are more comfortable with an FDA approved treatment. Patients who have anxiety about needles or IV access are natural Spravato candidates. The structured REMS protocol also appeals to patients who value a standardized, regulated treatment process.
Some patients benefit from starting with IV ketamine for rapid stabilization and then transitioning to Spravato for long term maintenance covered by insurance. This hybrid approach leverages the strengths of both treatments and gives providers flexibility in managing complex cases.
Offering Both Treatments in the Same Practice
Practices that offer both IV ketamine and Spravato capture a wider patient demographic. Cash pay patients seeking immediate access and personalized dosing choose IV ketamine. Insurance dependent patients with treatment resistant depression diagnoses and prior authorization approval choose Spravato. The dual model diversifies revenue and reduces dependence on either payer type.
Operational integration requires careful planning. Staff must maintain competency in both IV administration and REMS compliance. Scheduling systems need to accommodate the different session lengths: 40 to 60 minutes for IV ketamine versus two hours for Spravato. Inventory management splits between generic ketamine vials and REMS controlled Spravato devices.
Marketing benefits from the dual approach as well. A practice that offers both treatments positions itself as a comprehensive treatment resistant depression center rather than a single modality clinic. This positioning attracts more referrals from psychiatrists, primary care providers, and patients researching their options online.
Regulatory Landscape in 2026
The regulatory environment for ketamine therapy continues to evolve. IV ketamine remains available under the established framework of off label prescribing. State medical boards and the DEA regulate ketamine as a Schedule III controlled substance. Providers need a DEA registration and appropriate state licensure. No additional federal certification is required beyond standard controlled substance protocols.
Spravato operates under tighter federal oversight through the REMS program. Janssen and the FDA conduct periodic audits of certified treatment centers. Non compliance can result in loss of certification and inability to dispense the product. The REMS framework also limits distribution to certified settings, preventing take home use and ensuring every dose is administered under supervision.
At the state level, several states have introduced or passed legislation addressing ketamine clinic standards, staffing requirements, and patient safety protocols. Providers should stay current with their state medical board regulations and any emerging legislation that could affect practice operations. The trend moves toward more structure and oversight for all ketamine based treatments.
Decision Framework for Providers
Choosing between IV ketamine and Spravato, or deciding to offer both, comes down to five core factors. Use this framework to evaluate your practice’s readiness and strategy.
Patient population: If your patients are primarily cash pay and value speed, IV ketamine delivers. If your patients carry commercial insurance and their plans cover Spravato, the FDA approved path removes financial barriers and builds referral confidence.
Clinical priorities: Providers who prioritize dosing flexibility, rapid onset, and the ability to integrate psychotherapy into sessions lean toward IV ketamine. Providers who prioritize standardized protocols and FDA backed evidence lean toward Spravato.
Administrative capacity: REMS certification, specialty pharmacy coordination, and insurance billing demand dedicated administrative resources. Practices without strong back office support find IV ketamine operationally simpler. Practices with experienced billing teams and compliance officers handle Spravato’s requirements without strain.
Revenue goals: IV ketamine generates higher per session revenue with lower administrative cost. Spravato generates insurance based revenue with higher volume potential but thinner margins per session. Offering both maximizes total revenue by serving all payer types.
Growth strategy: A dual program positions the practice as the regional authority on treatment resistant depression. Referring providers send patients knowing the clinic will match the right treatment to the right patient. This reputation drives sustainable growth across both service lines.
The strongest practices in 2026 do not choose one path. They build infrastructure to deliver both treatments, train staff across both protocols, and guide each patient toward the option that best serves their clinical and financial situation. That comprehensive approach transforms a single modality clinic into a treatment resistant depression center of excellence.
Frequently Asked Questions
What is the difference between IV ketamine and Spravato?
IV ketamine uses racemic ketamine (both R and S enantiomers) delivered intravenously over 40 to 60 minutes. Spravato is esketamine (S enantiomer only) delivered as a nasal spray under clinical supervision with a 2 hour observation period. Spravato is FDA approved for depression while IV ketamine is off label.
Find a REMS-certified Spravato clinic near you in our verified provider directory.
Is IV ketamine more effective than Spravato?
Head to head trials are limited. Both treatments show similar response rates for treatment resistant depression, typically 50 to 70 percent. IV ketamine often produces faster acute relief, while Spravato offers a more structured long term protocol. Clinician choice often depends on insurance coverage and patient tolerance.
Can I do both IV ketamine and Spravato?
Some patients transition between the two based on response and insurance coverage. Combining them in the same day is not recommended due to cumulative dissociative effects. A psychiatrist can design a protocol that uses one during induction and the other for maintenance.
Which is cheaper, IV ketamine or Spravato?
Without insurance, IV ketamine is typically cheaper at $400 to $800 per session versus $850 to $1,600 per Spravato session. With insurance, Spravato is usually far cheaper because commercial plans and Medicare cover it, reducing patient cost to $10 to $125 per session.
